Adaptimmune Therapeutics Plc (ADAPY)
Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on cell therapies for cancer, with activities in the United States and the United Kingdom. The company’s listed security is an ADR, classified as a depositary receipt representing common stock, and it trades on OTC Markets under the symbol ADAP.Y. Adaptimmune’s pipeline includes TECELRA (afami-cel) for adults with unresectable or metastatic synovial sarcoma, Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, which is in Phase 1 testing for head and neck cancer. It is also developing T-cell therapies targeting PRAME and CD70. The company has collaboration arrangements with Galápagos, Noile-Immune Biotech, and MD Anderson Cancer Center. Founded in 2008, Adaptimmune is headquartered in Abingdon, United Kingdom.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ADAP.Y
|
$0.043
|
28.8% Upside
|
Undervalued
|
$1.50 4,445.5% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.1x
|
0.3x
|
1.8x
|
8.747 M
|
-1.399 M
|
61.7%
|
99.4%
|
-47.2
|
—
|
156.8%
|
